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When ingested in sufficient numbers, probiotics are expected to confer one or more proven
health benefits on the consumer. Theoretically, the effectiveness of a probiotic food product is
the sum of its microbial quality and its functional potential. Whereas the latter may vary much
with the body (target) site, deliverymode, human target population, andhealth benefit envisaged
microbial assessment of the probiotic product quality is more straightforward. The range of
stakeholders that need to be informed on probiotic quality assessments is extremely broad,
including academics, food and biotherapeutic industries, healthcare professionals, competent
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The Belgian Superior Health Council (SHC) draws up scientific ad-
visory reports that aim at providing guidance to political decision-
makers and health professionals. This advisory report does not dis-
cuss specific strains, products, or technologies, nor does it in any way
confer approval on products purported to have probiotic activity as
regards to any clinical effectiveness they might have in preventing or
treating pathologies (“health claim”).
Further detailed information on the work of the SHC can be found at
http://www.health.belgium.be/eportal/Aboutus/relatedinstitutions/
SuperiorHealthCouncil.
The advisory report was effectively released in February 2012.
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authorities, consumers, and professional press. In view of the rapidly expanding knowledge on
this subject, the Belgian Superior Health Council installedWorking Group “8651 Probiotics” to
review the state of knowledge regarding themethodologies that make it possible to characterize
strains and products with purported probiotic activity. This advisory report covers three main
steps in the microbial quality assessment process, i.e. (i) correct species identification and
strain-specific typing of bacterial and yeast strains used in probiotic applications, (ii) safety
assessment of probiotic strains used for human consumption, and (iii) quality of the final
probiotic product in terms of its microbial composition, concentration, stability, authenticity,
and labeling.
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1 Introduction
The word “probiotic” means “for life” (from the Greek o
βι´oς , pro bios). The works of Metchnikoff [1] and Tissier [2]
were the first to make scientific suggestions concerning the
probiotic use of bacteria, even when the word “probiotic”
was not coined until 1960, to name substances produced by
microorganisms that promoted the growth of other microor-
ganisms [3]. Some other definitions followed, with Fuller [4]
being the first pointing out the microbial nature of probi-
otics by redefining the word “probiotic” as “a live microbial
feed supplement that beneficially affects the host animal by
improving its intestinal balance”. Havenaar and Huis in’t
Veld [5] extended the definition as “a viable mono- or mixed
culture of bacteria which, when applied to animal or man,
beneficially affects the host by improving the properties of the
indigenous flora”. Guarner and Schaafsma [6] gave a more
recent definition as “live microorganisms, which when con-
sumed in adequate amounts, confer a health effect on the
host”.
According to the report of the joint “Food and Agricul-
ture Organization/World Health Organization (FAO/WHO)
Expert Consultation on Evaluation of Health and Nutritional
Properties of Probiotics in Food including Powder Milk with
Live Lactic Acid Bacteria” [7], probiotics were redefined for the
purpose of themeeting as: “Livemicroorganismswhichwhen
administered in adequate amounts confer a health benefit on
the host” (FAO/WHO, 2001). Following the FAO/WHO defi-
nition, the International Life Sciences Institute [8] and the Eu-
ropean Food and Feed Cultures Association [9] have launched
similar definitions for a probiotic, namely “a live microbial
food ingredient that, when taken up in adequate amounts,
confers health benefits on the consumers” and “live microor-
ganisms which, when ingested or locally applied in sufficient
numbers, provide the consumer with one or more proven
health benefits”, respectively.
The FAO/WHO expert consultation restricted its scope to
the discussion of probiotics “as part of the food” and excluded
reference to the term biotherapeutic agents and beneficialmi-
croorganisms not used in food. However, it is recognized that
the definition is sufficiently broad as to encompass a range of
probiotic preparations and intentions of use. In this respect,
a probiotic can be a food or a dietary supplement, can be
used in a drug application (also named a live biotherapeu-
tic) or microbial feed or can be used as genetically modified
microorganism (GMM) or live vaccine if administered orally.
For use in food, important criteria for probiotics were
documented, in particular that they shouldnot only be capable
of surviving passage through the digestive tract, by exhibiting
acid and bile tolerance and withstand digestive enzymes, but
also have the capability to proliferate in the gut. Probiotics
must be able to exert their benefits on the host through growth
and/or activity in the human body. Therefore, the ability to
remain viable at the target site and to be effective should be
verified for each strain.
In 2002, a joint FAO/WHO working group generated
Guidelines for the evaluation of Probiotics in Food [10]. It
was recommended to officially adopt the above FAO/WHO
definition of probiotics and to use and adopt the guidelines
in the report of this working group as a prerequisite to call
a microbial strain “probiotic”. The minimum requirements
needed for probiotic status include:
(i) the assessment of strain identity (genus, species, strain
level);
(ii) in vitro tests to screen potential probiotic strains:
e.g. resistance to gastric acidity, bile acid and diges-
tive enzymes, antimicrobial activity against potentially
pathogenic bacteria, etc.;
(iii) assessment of safety: requirements for proof that a pro-
biotic strain is safe and without contamination in its
delivery form;
(iv) in vivo studies for substantiation of health effects in the
target host.
The working group recommended that information accu-
mulated to show that a strain is a probiotic, including clin-
ical trial evidence, be published in peer-reviewed scientific
or medical journals. Also, publication of negative results is
encouraged, as to contribute to the totality of the evidence to
support probiotic efficacy.
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The recommendations of the above FAO/WHO Con-
sultation and the Guidelines of the FAO/WHO working
group have been assembled in one document [11] and
were presented to two Codex Alimentarius Committees:
the Codex Committee on Food Labeling and the Codex
Committee on Nutrition and Foods for Special Dietary
Uses. It is hoped that the work of the FAO/WHO pro-
biotics groups will be used as a model for future Codex
guidelines.
In relation to the substantiation of health effects of pro-
biotics in the target host, it is important to know that in
the European Union, health claims should only be autho-
rized for use in the Union after a scientific assessment of the
highest possible standard has been carried out by the Panel
on Dietetic Products, Nutrition, and Allergies (NDA) of the
European Food Safety Authority (EFSA) (Regulation (EC) No.
1924/2006) [12]. Key questions that are addressed by the EFSA
NDA panel are:
(i) is the food/constituent sufficiently defined and charac-
terized?
(ii) is the claimed effect sufficiently defined, and is it a ben-
eficial physiological effect?
(iii) have pertinent human studies been presented to sub-
stantiate the claim?
If the outcome of all of the above questions is favorable,
the panel weighs the evidence from all the pertinent studies
presented, including human, animal, in vitro, and mechanis-
tic studies.
The NDA panel has provided general guidelines on how
health claims related to gut and immune function are scientif-
ically evaluated [13]; these guidelines are particularly interest-
ing for probiotics that are usually expected to have this kind of
health effects. The guidelines are not intended as an exhaus-
tive list of beneficial effects and acceptable studies/outcome
measures, but rather present examples drawn from evalu-
ations already carried out to illustrate the approach of the
panel.
Finally, it should be emphasized that besides strain iden-
tification and characterization, survival of the passage of the
upper gastrointestinal tract, transient adhesion to or inter-
action with the intestinal epithelium, and colonization of
the colon and resistance of the strains toward technologi-
cal processing and storage are of utmost importance. This
underlines the importance of the food matrix and the ap-
plied process technology to prepare the food (constituent)
and the requirement for stability and survival of the strain
until the moment of consumption of the food. This in turn
points toward food matrix dependency (including amount
of food to be consumed for a proven health effect) and
the importance of an adequate amount of live active cells,
respectively.
In view of the rapidly expanding knowledge on this sub-
ject, this advisory report on the issue of probiotics provides
up-to-date information on the state of the art on themicrobio-
logical characterization of the concerned livemicroorganisms
(bacteria and yeasts).
2 Strain identification and typing
2.1 Microbial species used as probiotics
for human application
Awide range of product types containing viable or heat-killed
microorganismswith probiotic claims are commercially avail-
able either as fermented food commodities, foods with pro-
biotic ingredients, or in lyophilized form. In accordance to
the widely used FAO/WHO definition of probiotics [7], this
chapter will only deal with the identification and typing of live
microorganisms used as probiotics for human applications
(Table 1).
With the emphasis mainly on fermented dairy products, a
steadily increasing range of yogurt-like products is available in
the Europeanmarket. Probiotic strains used in these products
are generally, but not exclusively, derived from the gastroin-
testinal tract of presumed healthy humans. This is reflected
by the high frequency in which strains of autochthonous
Lactobacillus and Bifidobacterium species are applied in these
products [14–17] (Table 1). Lactobacillus is a member of the
lactic acid bacteria and is naturally occurring on raw food
and feed materials but is also a member of the intestinal
tract ofmostmammals. Although also a lactic acid-producing
bacterium, Bifidobacterium is not considered a typical mem-
ber of the LAB, due to its remote phylogenetic position. To
a lesser extent, also other LAB strains belonging to genera
such as Enterococcus, Lactococcus, and Pediococcus are used
as probiotics for humans mainly in dairy-based products. In
contrast, strains of non-LAB bacteria such as Bacillus, Propi-
onibacterium, and Eschericha coli used as probiotic are rarely
included in dairy or other food commodities, but are usually
applied as lyophilized or encapsulated pharmaceutical prepa-
rations. The use of yeasts in commercial probiotic products
is virtually restricted to a single strain commonly referred to
as Saccharomyces cerevisiae var. boulardii [18], although also
other nonpathogenic yeast strains have been the subject of
probiotic studies [19].
Importantly, not all microorganisms present in a probi-
otic product per definition have probiotic characteristics. A
typical example is the case of strains of the yogurt starters
Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus
thermophilus, which are applied mainly for technical reasons
but are not commonly regarded as probiotics. The latter point
is still under debate as literature searches have shown that
viable yogurt starter cultures have the potential to improve
lactose digestion and eliminate symptoms of lactose intoler-
ance [20].
The relevance of reliable identification and typing of
strains used in probiotic applications is still increasing be-
cause of the two main reasons. First, it is clear that the use
of probiotic strains is no longer strictly restricted to food
C© 2013 The Authors. Molecular Nutrition & Food Research published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.mnf-journal.com
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Table 1. Most important microorganisms applied in probiotic products for human usea–c)
Lactic acid bacteria Bifidobacterium Other bacteria Yeasts
Lactobacillus Bf. adolescentis Bacillus Saccharomyces
cerevisiae var.
boulardii
Lb. acidophilus Bf. animalis subsp. lactis Bc. cereusd) Saccharomyces spp.
Lb. casei/paracasei Bf. bifidum Bc. coagulans
Lb. crispatus Bf. breve Bc. clausii
Lb. fermentum Bf. longum subsp. infantis Bc. pumilus
Lb. gallinarum Bf. longum subsp. longum Bc. subtilis
Lb. gasseri Escherichia coli Nissle 1917d)
Lb. johnsonii Propionibacterium
Lb. plantarum Pr. acidipropionici
Lb. reuteri Pr. freudenreichii subsp. shermanii
Lb. rhamnosus Pr. jenseniid)
Lb. salivarius
Enterococcus faeciumd)
Lactococcus lactis subsp. lactis
Leuconostoc
Le. citreum
Le. mesenteroides subsp. cremoris
Oenococcus oeni e)
Pediococcus
Pd. acidilactici
Pd. pentosaceus
Sporolactobacillus inulinusd)
a) Adapted and updated from [14,15,17].
b) Up-to-date nomenclature of species names can be checked via http://www.bacterio.cict.fr/
c) Excluded are the yogurt starter cultures Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus thermophilus.
d) Species not included in the 2009 updated EFSA list of biological agents intentionally added to food or feed recommended for qualified
presumption of safety.
e) Probiotic properties have been documented in some strains of this species [205], but no applications for human use are currently known.
applications where history of safe use in (traditional) fer-
mented foods was an important argument to neglect the im-
portance of correct classification of probiotics. In recent years,
however, probiotics are also more and more used in biother-
apeutic and pharmaceutical applications, which are aimed at
specific patient groups each with their own clinical risk pro-
files. As a part of the biosafety evaluation in the course of this
type of clinical interventions, it is now commonly accepted
that correct identification to the species level and even to the
strain level is essential. Second, probiotic use no longer only
involves monocultures but in the meanwhile has also wit-
nessed the introduction of several mixed-strain formulations
in food products with health-promoting claims as well as in
therapeutic trials and applications. As part of any health claim
dossier, it is clear that the individual strains composing such
mixtures need to be fully characterized taxonomically.
2.2 Identification
At present, the inappropriate use of identification methods is
regarded as the major cause of incorrect species designations
of probiotic strains [21] and mislabeling of probiotic prod-
ucts [22–24]. Inconsistencies in the microbial identification
of commercial products with probiotic claims affects their
potential efficacy and safety record, and are likely to have a
negative impact on consumer trust.
2.2.1 Conventional phenotypic approaches for
bacterial identification
For identification of probiotic bacterial strains, phenotypic
tests or commercial miniaturized identification systems such
as Analytical Profile Index tests are inadequate for species
level resolution. In fact, it is recommended that biochemical
characterization should not be used as a stand-alone approach
for identification of any probiotic culture. Commercial iden-
tification systems may be useful to obtain a first tentative
classification at the genus level in conjunction with primary
phenotypic tests, but the identification result should in any
case be confirmed by other (molecular) methods. It is impor-
tant to highlight that the usefulness of (commercial) biochem-
ical systems for identification of probiotic bacterial strains is
limited, due to the high intraspecific phenotypic variability
observed in many bacterial species, and due to the fact that
updates of the identification databases linked to these sys-
tems are slow or even missing, are often incomplete, and
that species entries are poorly documented without listing
the reference strains used [25].
C© 2013 The Authors. Molecular Nutrition & Food Research published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.mnf-journal.com
Mol. Nutr. Food Res. 2013, 00, 1–26 5
2.2.2 Molecular approaches
for bacterial identification
Despite the event of sequence-based approaches, DNA–
DNA reassociation is currently considered as the “gold
standard” for delineation and description of new bacterial
species, but is impractical in routine identification of bac-
terial cultures. Other molecular methods are therefore pre-
ferred provided that they offer sufficient experimental re-
producibility and a proper taxonomic resolution and that
they make use of updated and easily available and vali-
dated identification databases. The use of molecular ap-
proaches for identification of species used in probiotic ap-
plications is covered in large detail in several review articles
[14, 15, 26].
Sequence analysis of the partial or complete 16S ribo-
somal RNA (rRNA) gene is now commonplace as the first
tool to use for the taxonomic positioning of probiotic cul-
tures [27]. Next to the universal distribution of this gene in
all bacterial species, which avoids the use of group-specific
protocols, other obvious advantages of using this and other
sequence-based methods include the high level of data re-
producibility and exchangeability. Sequencing is now com-
monly outsourced to specialized service providers and se-
quencing centers, often with satisfactory to excellent results.
The major bottleneck of the 16S rRNA gene sequencing ap-
proach for nonexperienced users, however, is the taxonomic
interpretation of the sequence data by comparison with pub-
lic sequence databases such as European Molecular Biol-
ogy Laboratory (http://www.ebi.ac.uk/embl/) and GenBank
(http://www.ncbi.nlm.nih.gov/genbank/). These databases
often contain loads of unreliable, poorly documented, or
incomplete sequence entries, which may compromise the
accuracy of the identification result. Therefore, experienced
users will have to make sure that only validated and com-
plete 16S rRNA gene sequences are used for identification
purposes and that full 16S rRNA gene sequences of multiple
taxonomic reference strains per taxon (certainly including
the type strain) are included in the identification database
to encompass the genomic variation within the taxon. The
Ribosomal Database Project (http://rdp.cme.msu.edu/) and
the Silva rRNA database project (http://www.arb-silva.de/)
are two free web-based applications that provide ribosome-
related data and services to the scientific community, includ-
ing online data analysis and aligned and annotated 16S rRNA
gene sequences.
In addition to their use for straightforward identification of
pure cultures, ribosomal sequences have also been exploited
for culture-independent detection of probiotic microorgan-
isms. The use of rRNA-targeted probes provides a unique in-
sight into the dynamics of probiotic microorganisms in com-
plex microbial communities. Nucleic acid probes have been
designed to specifically target taxonomic groups at different
levels of specificity (from genus to strain). The review by Ben
Amor et al. [28] presents a good overview of the currently avail-
able and validated 16S rRNA-targeted oligonucleotide probes
for the identification of LAB ranging from group and genus
to species and subspecies level.
Despite its obvious advantages, it has been shown that 16S
rDNA sequencing has a limited resolution for the discrimi-
nation of very closely related species, including those that are
frequently used in probiotic foods and preparations. Within
the genus Lactobacillus, for example, some species of the L.
delbrueckii group, the Lactobacillus casei group, and the Lacto-
bacillus plantarum group are difficult to separate even when
using full 16S rRNA gene sequences [16, 29]. In the case the
probiotic strain belongs to one of these species, results of
16S rRNA gene sequence identification may only be reliable
at the genus level and need to be complemented by other
molecular methods to obtain classification at (sub)species
level [21]. To this end, a series of DNA fingerprinting meth-
ods including repetitive DNA element (rep)-PCR, amplified
fragment length polymorphism (AFLP), amplified riboso-
mal DNA restriction analysis, and tDNA intergenic spacer
PCR have been evaluated and optimized for species iden-
tification of most probiotic microorganisms (Table 2). In
contrast to sequence-based approaches, however, fingerprint
data are much less exchangeable and reproducible between
laboratories and strongly rely on the availability of an ex-
tended and up-to-date database of reference profiles. For this
reason, fingerprint-based identifications are best performed
in expert labs that use standardized protocols and have ac-
cess to in-house databases for identification of unknown
cultures.
The use of protein-encoding housekeeping genes essen-
tially combines the technological advantages of 16S rRNA
gene sequencing and the taxonomic resolution of many
fingerprinting methods. Sequencing of one or preferably
multiple of these genes as taxonomic markers is a crucial
step forward in the development of standardized and globally
accessiblemethods for the identification of probiotic cultures.
For LAB, the combined sequence analysis of the atpA, pheS,
and rpoA genes has been successfully explored for species
identification of enterococci [30], lactobacilli [31], leuconos-
tocs [32], and pediococci [33]. Analysis of partial hsp60 [34]
and rpoB [35] gene sequences have proven to be useful single-
locus approaches for the differentiation of Bifidobacterium
spp. However, concatenation of partial sequences of seven
genes (clpC, dnaB, dnaG, dnaJ1, purF, rpoC, and xfp) may
significantly increase the discriminatory power between bifi-
dobacterial species [36]. Within the Bacillus subtilis group and
related taxa, the housekeeping genes, gyrB [37] and rpoB [38],
are often used for reliable species differentiation.
Themost recent insights fromwhole-genome sequencing
have indicated that even conserved genes such as protein-
encoding housekeeping genes may be subjected to genomic
rearrangements such as deletions, duplications, mutations,
recombinations, and lateral gene transfer. This important
finding thus suggests that the classification of microorgan-
isms may not be accurately reflected by analyzing the se-
quences of one gene or a cluster of genes. The current
availability of complete genome sequences of thousands of
C© 2013 The Authors. Molecular Nutrition & Food Research published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.mnf-journal.com
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Table 2. DNA fingerprinting methods used for identification and/or typing of probiotic microorganisms
Method LAB Bifidobacterium Bacillus Propionibacterium Saccharomyces
AFLP [21,57]
ARDRA [206,207] [211–213] [219]
ITS analysisa) [217] [220] [68–70]
PFGE [56–58,208] [23,54,55] [53] [68]
RAPD [52] [53] [68,69]
rep-PCRb) [21,56,209,210] [214–216] [218] [221,222]
a) Includes sequencing and/or restriction analysis of ribosomal ITS elements.
b) Targets repetitive elements such as (GTG)5, ERIC, and BOX for bacteria and M13 for yeasts.
bacterial strains allows to investigate new avenues for bac-
terial phylogeny and identification. The average amino
acid identity and the average nucleotide identity [39, 40]
are two parameters resulting from pairwise genome com-
parisons and averaging the sequence identities of shared
orthologous genes (amino acid or nucleotide, respec-
tively) that are already being used to compare whole-
genome sequences for taxonomic purposes and, ulti-
mately, to describe new bacterial species. Within the
LAB and Bifidobacterium species used as probiotics for
human applications, the complete genome sequences of
more than 60 strains have been submitted to GenBank
(Table 3).
Finally,MSmethods are becoming increasingly important
for classification and identification of bacteria [41]. One of
these methods, MALDI-TOFMS, allows to measure peptides
and other compounds in the presence of salts and to analyze
complex peptide mixtures which make it an ideal method for
measuring nonpurified extracts and intact bacterial cells. The
resultant MALDI-TOF MS spectra can be used to generate
identification libraries for simple and high-throughput iden-
tification of unknown bacterial isolates. These reference li-
braries can either be constructed or provided on a commercial
basis, such as the one integrated in the MALDI Biotyper sys-
tem (Bruker Daltonics, Bremen, Germany), or can be gener-
ated on a local basis. Such local databases have been success-
fully used for the identification of Lactococcus lactis [42], the
LAB genera Leuconostoc, Fructobacillus, and Lactococcus [43],
LAB from traditional fermented foods [44], and the Lb. ca-
sei group [45]. Angelakis et al. [46] used a combination of
commercial and local databases to successfully identify LAB
and Bifidobacterium species present in probiotic drinks and
yogurts.
2.2.3 Yeast identification
Identification and classification of yeasts have traditionally
been based on morphological, physiological, and biochem-
ical traits. Various commercial biochemical kits have been
developed for rapid yeast identification, but mostly for the
clinical market. Currently, different molecular biology tech-
niques are available for identification of yeasts.
A reliable starting point for the identification of pro-
biotic yeasts is the D1/D2 large subunit rRNA gene se-
quence database, which encompasses virtually all known
yeast species [47]. However, due to the fact that some dis-
tinct species show low-sequence divergence, the use ofD1/D2
large subunit sequences is often complemented by PCR am-
plification of repetitive DNA elements [48] and by determina-
tion of additional gene sequences, such as the internal tran-
scribed spacer (ITS) region of the rRNA gene cluster [49] or
protein-coding genes such as the actin gene (ACT1; [50]),
and the mitochondrial cytochrome oxidase 2 (COX2) and
cobalamin-independent methionine synthase (MET6) genes
[51].
2.3 Typing
2.3.1 Bacteria
In many cases, it is highly important to characterize probi-
otic cultures at the individual strain level, a process generally
referred to as typing. Such cases may include screening large
microbiological collections for probiotic candidates, monitor-
ing selected candidate strains during in vitro and in vivo trials,
quality control of probiotic products, strain authentication in
legal matters, and epidemiological surveys.
To a large extent, typing of probiotic microorganisms still
relies on the use of molecular methods [15]. Several fin-
gerprinting methods that have been used for species iden-
tification such as (rep)-PCR and AFLP are also suitable as
typing methods up to the strain level (Table 2). Especially
in the case of AFLP, the flexibility in choice of specific re-
striction enzymes and selective PCR primers allows to test
multiple combinations, which can significantly increase the
discriminatory power at strain level. Depending on the num-
ber of isolates to be processed, the required speed of perfor-
mance, and the expertise of the user, also randomly amplified
polymorphic DNA (RAPD) and pulsed-field gel electrophore-
sis (PFGE) can be applied for typing of probiotic strains
(Table 2). RAPD allows fast and reliable comparison of larger
sets of isolates in a single PCR run, but often lacks the same
level of reproducibility offered by other PCR-based finger-
printing techniques, which is an important prerequisite for
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Table 3. List of complete genome sequences of Bifidobacterium and LAB species used as probiotics for human applicationsa),b)
Strainc) GenBank Accession Number NCBI RefSeq Numberd)
Bf. adolescentis ATCC 15703 AP009256.1 NC_008618.1
Bf. animalis subsp. lactis AD011 CP001213.1 NC_011835.1
Bf. animalis subsp. lactis B420 CP003497.1 NC_017866.1
Bf. animalis subsp. lactis BB-12e) CP001853
Bf. animalis subsp. lactis BLC1 CP003039.1 NC_017216.1
Bf. animalis subsp. lactis Bi-07 CP003498.1 NC_017867.1
Bf. animalis subsp. lactis B1–04 CP001515.1 NC_012814.1
Bf. animalis subsp. lactis CNCM I-2494 CP002915.1 NC_017215.1
Bf. animalis subsp. lactis DSM 10140 CP001606.1 NC_012815.1
Bf. animalis subsp. lactis V9 CP001892
Bf. bifidum BGN4 CP001361.1 NC_017999.1
Bf. bifidum PRL2010 CP001840.1 NC_014638.1
Bf. bifidum S17 CP002220.1 NC_014616.1
Bf. breve ACS-071-V-Sch8b CP002743.1 NC_017218.1
Bf. breve UCC2003 CP000303.1
Bf. longum DJO10A CP000605.1 NC_010816.1
Bf. longum NCC2705 AE014295.3 NC_004307.2
Bf. longum subsp. infantis ATCC 15697 CP001095.1 NC_011593.1
Bf. longum subsp. infantis 157F AP010890.1 NC_015052.1
Bf. longum subsp. longum BBMN68 CP002286.1 NC_014656.1
Bf. longum subsp. longum F8 FP929034
Bf. longum subsp. longum JCM 1217 AP010888.1 NC_015067.1
Bf. longum subsp. longum JDM301 CP002010.1 NC_014169.1
Bf. longum subsp. longum KACC 91563 CP002794.1 NC_017221.1
Lb. acidophilus 30SC CP002559.1 NC_015214.1
Lb. acidophilus NCFM CP000033.3 NC_006814.3
Lb. amylovorus GRL 1112 CP002338
Lb. amylovorus GRL1118 CP002609.1 NC_017470.1
Lb. casei ATCC 334 CP000423.1 NC_008526.1
Lb. casei BD-II CP002618.1 NC_017474.1
Lb. casei BL23 FM177140.1 NC_010999.1
Lb. casei LC2W CP002616.1 NC_017473.1
Lb. casei str. Zhang CP001084.1 NC_014334.1
Lb. crispatus ST1 FN692037.1 NC_014106.1
Lb. delbrueckii subsp. bulgaricus 2038 CP000156.1 NC_017469.1
Lb. delbrueckii subsp. bulgaricus ATCC 11842 CR954253.1 NC_008054.1
Lb. delbrueckii subsp. bulgaricus ATCC BAA-365 CP000412.1 NC_008529.1
Lb. delbrueckii subsp. bulgaricus ND02 CP002341.1 NC_014727.1
Lb. fermentum CECT 5716 CP002033
Lb. fermentum IFO 3956 AP008937.1 NC_010610.1
Lb. gasseri ATCC 33323 CP000413.1 NC_008530.1
Lb. johnsonii DPC 6026 CP002464.1 NC_017477.1
Lb. johnsonii FI9785 FN298497.1 NC_013504.1
Lb. johnsonii NCC 533 AE017198.1 NC_005362.1
Lb. plantarum JDM1 CP001617.1 NC_012984.1
Lb. plantarum WCFS1 AL935263.1 NC_004567.1
Lb. plantarum subsp. plantarum ST-III CP002222.1 NC_014554.1
Lb. reuteri DSM 20016 CP000705.1 NC_009513.1
Lb. reuteri JCM 1112 AP007281.1 NC_010609.1
Lb. reuteri SD2112 CP002844.1 NC_015697.1
Lb. rhamnosus ATCC 8530 CP003094.1 NC_017491.1
Lb. rhamnosus GGe) FM179322.1 NC_013198.1
Lb. rhamnosus GGe) AP011548
Lb. rhamnosus Lc 705 FM179323.1 NC_013199.1
Lb. salivarius CECT 5713 CP002034
Lb. salivarius UCC118 CP000233.1 NC_007929.1
Lc. lactis subsp. cremoris A76 CP003132.1 NC_017492.1
Lc. lactis subsp. cremoris MG1363 AM406671.1 NC_009004.1
Lc. lactis subsp. cremoris NZ9000 CP002094
Lc. lactis subsp. cremoris SK11 CP000425.1 NC_008527.1
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Table 3. Continued
Strainc) GenBank Accession Number NCBI RefSeq Numberd)
Lc. lactis subsp. lactis CV56 CP002365.1 NC_017486.1
Lc. lactis subsp. lactis Il1403 AE005176.1 NC_002662.1
Lc. lactis subsp. lactis KF147 CP001834.1 NC_013656.1
Le. citreum KM20 DQ489736.1 NC_010471.1
Le. mesenteroides subsp. mesenteroides ATCC 8293 CP000414.1 NC_008531.1
Le. mesenteroides subsp. mesenteroides J18 CP003101.1 NC_016805.1
O. oeni PSU-1 CP000411.1 NC_008528.1
Pd. pentosaceus ATCC 25745 CP000422.1 NC_008525.1
S. thermophilus CNRZ1066 CP000024.1 NC_006449.1
S. thermophilus JIM 8232 FR875178.1 NC_017581.1
S. thermophilus LMD-9 CP000419.1 NC_008532.1
S. thermophilus MN-ZLW-002 CP003499.1 NC_017927.1
S. thermophilus LMG 18311 CP000023.1 NC_006448.1
S. thermophilus ND03 CP002340
a) Last updated on September 5, 2012.
b) Considering their importance in yogurt production, strains of Lb. delbrueckii subsp. bulgaricus and S. thermophilus were also included
in the table.
c) The species name as mentioned in the Complete Microbial Genomes list of NCBI (http://www.ncbi.nlm.nih.gov/genomes/lproks.cgi) is
not necessarily in accordance to the current bacterial nomenclature.
d) The Reference Sequence (RefSeq) database of NCBI provides a comprehensive standard dataset that represents sequence information
for a species. RefSeq sequences are derived from GenBank records but differ in that each RefSeq is a synthesis of information, not an
archived unit of primary research data.
e) Strains used as probiotics.
database construction. Nevertheless, RAPD is still frequently
used to discriminate between probiotic strains [52, 53]. To-
gether with AFLP, by far the highest resolution at strain level
can be achieved by PFGE. Although the latter method can
be standardized, it requires a dedicated electrophoretic unit
and considerable technical expertise. PFGE fingerprinting
has been successfully used to differentiate or track probiotic
strains in the genera Bifidobacterium [23, 54, 55], Lactobacil-
lus [56–58], and Bacillus [59].
In addition to DNA fingerprinting, also sequence-based
approaches have been used to discriminate or detect
individual probiotic strains. The availability of complete
genome sequences of probiotic strains not only broadens our
biological knowledge of their functional potential, but also
offers a myriad of new possibilities for strain differentiation.
Based on internal nucleotide sequences of multiple (usually
three to seven) housekeeping genes, several multilocus
sequence typing (MLST) schemes have been developed for
discrimination between bacterial isolates at the intraspecific
level. For each gene, 450–500 bp internal fragments with a
maximal number of polymorphisms are selected for ampli-
fication and subsequent gene sequence analysis. For each
housekeeping gene, the different sequences present within a
bacterial species are assigned as distinct alleles and, for each
isolate, the alleles at each of the loci define the allelic profile
or sequence type. The MLST method has several advantages,
including reproducibility and data exchangeability and can
be automated to a large extent. While MLST is primarily used
to study population structure, evolution, and phylogeography
of bacterial pathogens [60], depending on the species it
also provides good discriminatory power to differentiate
isolates for typing purposes. For bacteria, MLST schemes
were first developed for clinically relevant microorganisms
such as Enterococcus faecium (http://efaecium.mlst.net [61])
and Bacillus cereus (http://pubmlst.org/bcereus/ [62]). In
recent years, MLST schemes have also been developed
for several other species commonly applied as probiotics.
MLST schemes relevant for typing of probiotic Lactobacilli
include those developed for the species Lb. casei [63, 64], Lb.
plantarum [65], and Lb. salivarius [66]. Recently, an MLST
scheme was made available for the probiotic Bifidobac-
terium species Bf. animalis, Bf. bifidum, Bf. breve, and Bf.
longum [67]. Similar to the mlst.net database for bacterial
pathogens, MLST sequence type databases have been
launched, for example, for Lb. casei (http://www.pasteur.
fr/recherche/genopole/PF8/mlst/Lcasei.html) andBifidobac-
terium (http://www.pasteur.fr/recherche/genopole/PF8/mlst
/Bifidobacterium.html). These public databases allow queries
and downloads of allele sequences and allelic STs, provide
several database tools and statistics, and are also open to
additional data on novel strains and species.
In addition to MLST approaches, analysis of whole-
genome sequences through comparative genomics can be
very useful to identify unique gene sequences that allow to
discriminate a given probiotic culture from other members
of the same species. Such strain-specific target sequences
can then be used to detect a given probiotic in complex en-
vironments, such as food matrices or fecal samples, without
the need for culturing. Instead, culture-independent meth-
ods such as fluorescent in situ hybridization and real-time
PCR are employed for direct detection and enumeration of
the target strain in the sample.
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2.3.2 Yeasts
Typing of probiotic yeasts has largely been based on in-
traspecies polymorphisms located in the ITS regions of the
ribosomal gene cluster. As an alternative to ITS sequencing,
restriction fragment length polymorphism analysis of ampli-
fied ITS regions has been used to differentiate Saccharomyces
yeasts isolated from various commercial probiotic and bio-
therapeutic products claimed to contain S. cerevisiae or “S.
boulardii” [68]. In the latter study, the ITS-based approach
was combined with RAPD and PFGE fingerprinting to differ-
entiate S. cerevisiae var. boulardii strains from other strains
in the species. Discrimination of individual strains within S.
cerevisiae is unlikely with a single typing technique [69]. In
a comparative study with ITS-based approaches, microsatel-
lite DNA polymorphism analysis and retrotransposon Ty917
hybridization analysis were considered to offer the highest
discriminatory power to distinguish probiotic and clinical S.
cerevisiae var. boulardii isolates from other clinical S. cerevisiae
isolates [70]. More recent developments in typing of S. cere-
visiae strains focus on the design of MLST schemes. So far,
the MLST approach has mainly been applied in wine yeast
typing but does not seem to offer the same level of resolution
as microsatellite analysis [71].
3 Safety assessment
3.1 Introduction
In general, the microorganisms used in the production
of food fermentation have a long history of safe use and
are often referred to as “food grade” or GRAS (Generally
Recognized As Safe) microorganisms [14]. Hence, this is
the case for most LAB and bifidobacteria [72–74]. In Eu-
rope, the qualified presumption of safety (QPS) concept ex-
ists with a list of microorganisms that can be considered
safe for use. The microorganisms intended for human use
are regulated in the EU in the context of novel food reg-
ulation (Regulation (EC) No. 258/97; http://ec.europa.eu/
food/food/biotechnology/novelfood/index_en.htm). For mi-
croorganisms (probiotics) used as additives in animal feed
(Regulation (EC) No. 1831/2003), official guidelines for their
safety assessment have been fixed at EU level by Regulation
(EC) No. 429/2008.
In recognition of the importance of assuring their safety
for human purposes, even among LAB that are generally con-
sidered to have a very good safety record, new and existing
probiotic strains need to be characterized with respect to a
number of safety aspects. Epidemiological surveillance stud-
ies are very important to evaluate the risk of probiotics used
in a specific population. In general, four types of side ef-
fects of probiotics can be distinguished: systemic infections,
metabolic and enzymatic effects, immunomodulation and
adjuvants, and gene transfer. Among these, the most direct
safety risk associated with the consumption of microorgan-
isms is infection (e.g. endocarditis), especially in immuno-
compromised individuals. In general, the risk of infection by
probiotic Lactobacillus or Bifidobacterium strains is similar to
the risk of infection by commensal strains, and thus products
containing such probiotic strains present a negligible risk to
consumers [75]. On the other hand, some strains of other
LAB groups such as enterococci are agents of opportunis-
tic infections. Rare cases of infection associated with certain
Lactobacillus strains have been reported, mostly in im-
munocompromised patients [76]. Bifidobacteria are ex-
tremely rarely associated with infections [77].Bifidobacterium-
associated infections are most likely caused by bifidobacteria
from the patients’ own microbiota [78,79]. A recent study re-
ported that the administration of the probiotic E. coli strain
Nissle 1917 to immunocompromised patients may lead to
severe adverse effects [80].
To establish safety guidelines for probiotic microorgan-
isms, an FAO/WHO working group recommended that pro-
biotic strains are characterized by a series of tests including
antibiotic resistance, metabolic activities, toxin production,
hemolytic activities, infectivity in immunocompromised an-
imal models, side effects in humans, and adverse outcomes
in consumers [10].
Although still under debate, it is generally agreed that
probiotic safety aspects should cover the isolation history and
species identity of the probiotic culture and provide pheno-
typic and/or genotypic evidence showing that the culture does
not harbor acquired antibiotic resistance traits, putative vir-
ulence factors, or other pathogenic properties [25, 81, 82]. In
addition, it has been suggested that translocation, adhesion,
and colonizationmay also contribute to the safety dossier of a
probiotic strain. However, current problems in method stan-
dardization and data interpretation may need to be solved
first before the usefulness of these parameters can be truly
accepted.
3.2 Isolation history and taxonomic characterization
Although still a matter of debate, it has been suggested
that probiotic strains should originate from the species of
intended use. One can argue that a probiotic strain orig-
inating from the gastrointestinal tract of a healthy hu-
man can function better in a similar environment from
where it was originally isolated. Although this point of
view has been supported by the fact that most cur-
rent successful strains are indeed of human origin, some
animal-derived strains have also shown positive effects on
humans.
In addition to documenting its strain history, the first
step in (a) microorganism(s) or product being referred to
as a probiotic is to identify the microorganism using inter-
nationally accepted methodologies, preferably by combining
phenotypic and genotypic methods. The practical approaches
for accurate determination of species identity of probiotic cul-
tureshave beendiscussed extensively elsewhere in this report.
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Correct identification at species level also implies the use of
scientifically recognized names and adequate designation of
particular strains. The current state of evidence suggests that
different strains can possess different features related to dif-
ferent safety risks, implying that it is not possible to identify
the specific safety risks associated with a probiotic strain with-
out proper identification. Reliable identification is also nec-
essary to avoid the inclusion of pathogenic microorganisms
in probiotic products.
3.3 Antimicrobial resistance
Due to the indiscriminate use of antibiotics in human and
veterinary medicine and as animal growth promoters, antibi-
otic resistance has become an increasingly common charac-
teristic in (food borne) microorganisms [83], causing serious
problems in treatment of microbial infections. Antibiotic re-
sistance in bacteria may be intrinsic or acquired. Intrinsic
resistance is a naturally occurring trait that may be charac-
teristic for a given species or genus, whereas acquired resis-
tance derives either from genetic mutations or acquisition of
foreign DNA from other bacteria. Probiotic strains with non-
transmissible antibiotic resistances do not usually confer a
safety concern. To some extent, nontransmissible antibiotic
resistance might even be a useful property, if the probiotic
strain is to be used as a prophylactic agent in the treatment of
antibiotic-associated diarrhea [84,85]. However, antibiotic re-
sistance linked to transferable plasmids andmobile elements
is a different case because of the possibility of resistance
spreading to other, potentially more harmful bacteria. In the
end, such increases in the dissemination of antibiotic resis-
tance genes candrastically reduce the therapeutic possibilities
in infectious diseases. Given the documented presence of an-
tibiotic resistance genes in LAB and the indirect evidence that
these genes could be transferred along the food chain [86–88],
it is therefore relevant to assess the presence of transferable
antibiotic resistances in LAB strains that are or shall be used
as probiotics for human consumption, an opinion which is
adopted by EFSA [89]. Different expert panels have indicated
that strains harboring transferable antibiotic resistance genes
are not suitable for use as probiotics [25, 90]. In this context,
the specific risks related to each probiotic strainmust be care-
fully identified.
For phenotypic antimicrobial susceptibility testing of
bacterial species with clinical relevance such as enterococci,
enterobacteria and certain Bacillus species, expert committees
such as those appointed by the Clinical and Laboratory Stan-
dards Institute (CLSI; www.clsi.org/) and the British Society
for Antimicrobial Therapy (BSAC; www.bsac.org.uk/) have
proposed a series of standardized and harmonized methods
that can be easily performed in most routine labs. However,
for nonenterococcal LAB and bifidobacteria, which together
account for the vast majority of probiotic cultures currently
used, no such standards are available from CLSI, BSAC, or
other committees. As a result, a variety of noncongruent
methods and protocols for the determination of antibiotic
susceptibilities of nonenterococcal LAB have been reported
in the literature using agar (overlay) disc diffusion, E-test,
broth dilution, and agar dilution [91]. In general, dilution
methods and E-test are preferred as reference methods over
conventional diffusion-based tests, as the former techniques
allow determining minimal inhibitory concentration (MIC)
values that provide a more reliable indication of the intrinsic
or acquired nature of a given resistance phenotype. However,
due to the fact that many nonenterococcal LAB require
specific growth conditions in terms of medium acidity
and carbohydrate supplementation, conventional media
such as Mueller–Hinton (as recommended by CLSI) and
Iso–Sensitest agar (as recommended by BSAC) are not
suitable for susceptibility testing of probiotic lactobacilli,
pediococci, lactococci, and bifidobacteria. In the course of the
EU project PROSAFE, two new test medium formulations
have been developed for antimicrobial susceptibility testing
of nonenterococcal LAB [91]. The resulting LAB susceptibility
test medium (LSM) consists of a mixture of Iso-Sensitest
broth (90% v/v) and de Man-Rogosa-Sharpe (MRS) broth
(10% v/v), supplemented with 0.3 g/L L-cysteine hydrochlo-
ride for bifidobacteria. The use of the LSM formulation
has further been substantiated in another EU project,
which is Assessment and Critical Evaluation of Antibiotic
Resistance Transferability in the Food Chain (EU-FP6
project) (www.aceart.net), which resulted in the proposal to
use this medium as a standard medium for susceptibility
testing of lactobacilli and bifidobacteria from food and
nonfood origin. Recently, the intra and interlaboratory
performance of the LSM medium and related formulations,
specifically adapted for MIC testing of bifidobacteria, S.
thermophilus and L. lactis, has been positively evaluated in a
small-scale harmonization study [92]. In parallel, a standard
operating procedure, based on data from the PROSAFE and
Assessment and Critical Evaluation of Antibiotic Resistance
Transferability in the Food Chain (EU-FP6) projects, has
been validated as an official shared standard of ISO/IDF
(International Dairy Federation), i.e. ISO 10932:2010 (IDF
223:2010) standard “Milk and Milk Products – Determi-
nation of the Minimal Inhibitory Concentration (MIC) of
Antibiotics Applicable to Bifidobacteria and Non-Enterococcal
Lactic Acid Bacteria” (www.iso.org/iso/iso_catalogue/
catalogue_tc/catalogue_detail.htm?csnumber= 46434).
The interpretation of MIC data in order to decide whether
a (potential) probiotic strain harbors an acquired or atypi-
cal antibiotic resistance trait highly depends on the availabil-
ity of epidemiological cut-off values. The European Commit-
tee on Antimicrobial Susceptibility Testing (www.eucast.org)
has proposed a number of definitions toward a uniform
MIC interpretation. A microorganism is either defined as
a wild-type (WT) or nonwild-type (NWT) member of a
species by the absence or presence, respectively, of acquired
and mutational resistance mechanisms to the antimicrobial
agent in question. The strain in question is categorized as
WT or NWT within a species based on the cut-off values
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appropriate for that species and determined with a defined
phenotypic test system. This cut-off value will not be al-
tered by changing circumstances and WT microorganisms
may or may not respond clinically to antimicrobial treatment
(www.srga.org/eucastwt/eucastdefinitions.htm). Ideally, cut-
off values are defined at the species level, not at the genus
level. In this respect, the availability of correct species identi-
fication is an important prerequisite to define such species-
specific cut-off levels. For a range of Lactobacillus species or
species groups, including Lb. delbrueckii group, Lb. plantarum,
Lb. sakei, Lb. rhamnosus, Lb. paracasei group, Lb. reuteri, and
Lb. fermentum, specific MIC distributions and tentative cut-
off values for a range of antibiotics have been proposed [93].
Importantly, these data were obtained using a standard pro-
tocol that is largely compatible with the experimental proce-
dures outlined in ISO 10932:2010 (IDF 223:2010). Likewise,
MIC distribution data for several important bifidobacterial
taxa, including Bf. adolescentis group, Bf. longum group, Bf.
bifidum, Bf. catenulatum group, and Bf. animalis, have been
published [94].
Probiotic cultures belonging to the NWT population of a
species and thus in which phenotypic resistance has been de-
tected may have acquired antibiotic resistance genes located
on plasmids or (conjugative) transposons that may be further
transmitted to other microorganisms. The other possibility,
i.e. that the antibiotic resistance is due to mutations of chro-
mosomal housekeeping genes, represents a neglectable risk
of horizontal dissemination. Verification of the presence of
antibiotic resistance genes is thus crucial and can be achieved
by the use of dedicated PCR assays when a very specific re-
sistance trait is targeted. The majority of acquired resistance
genes so far found in (probiotic) LAB and bifidobacteria are
those conferring resistance to tetracycline (i.e. tet genes) and
erythromycin (i.e. erm genes). PCR primers specific for tet
and erm genes are published and have been validated for
use in Lactobacillus and Bifidobacterium [95, 96]. In the case
that the potential presence of multiple, rare, or silent (i.e.
not phenotypically detectable) resistance genes needs to be
verified, the use of dedicated microarrays [97, 98] can be
recommended.
If the presence of one or multiple resistance genes
is verified, the next step in the risk safety assessment
could be to check transfer of the gene(s) under experi-
mental conditions [87, 99]. However, failure to demonstrate
in vitro horizontal gene transfer does not exclude the risk
of dissemination of genes. Thus, while negative transfer
experiments do not provide evidence for the absence of
transfer, standardized transfer methods are still required
to estimate whether the probability for resistance trans-
fer is low or high. A standardized conjugation protocol
has been developed and validated by several laboratories
to asses antibiotic resistance transfer between lactococcal
species [100]. However, such protocols still need to be estab-
lished for in vitro transfer experiments with lactobacilli and
bifidobacteria.
3.4 Virulence and pathogenic properties
In general, potential probiotic strains should be screened
in vitro for their interactions with cell lines to investigate
possible cytotoxic or cytopathological effects after growth in
different media, for the presence of known virulence genes
(e.g. lecithinase activity, toxin genes) and for the presence
of mobile genetic elements. After these in vitro tests for po-
tentially safe use, in vivo toxicity tests and persistence stud-
ies would be required. A recent study by Hu¨tt et al. [101]
shows how to evaluate the in vivo safety and persistence of
Lactobacillus strains in the gastrointestinal tract of healthy
adult volunteers after oral consumption of high doses of
lactobacilli.
The long history of safe use of probiotic LAB is the best
evidence for the safety of probiotic products. Lactococcus and
Lactobacillus are most commonly given the “generally recog-
nized as safe” or GRAS status. Other LAB genera like Strep-
tococcus and Enterococcus and other genera that could be used
as probiotics contain opportunistic pathogens [102]. The ab-
sence of pathogenicity of any potential probiotic strain must
be shown to prove its safety. It should be addressed that in
general the number of infectionswith Lactobacillus strains are
very low. For instance, the risk of Lactobacillus infections is es-
timated at about one case per 10million people over a century
of probiotic consumption in France [103]. Even after perform-
ing different clinical trials and human studies, including one
involving enteral feeding of premature infants with a com-
mercial Lactobacillus rhamnosus strain called GG (title of the
strain derived from the names of Goldin and Gorbach), no
pathogenic potential could be indicated [104]. However, a
recent review [76] reported all cases of lactobacillemia identi-
fied through a Medline search of articles published between
1950 and 2003. From the 241 cases identified, lactobacilli
were implicated in endocarditis, bacteremia, and localized
and other infections. Lactobacillus casei and Lb. rhamnosus
(among which a case due to consumption of large quanti-
ties of fermented milk with the probiotic strain GG in the
months before hospitalization; [105]) were the species most
commonly responsible for these pathologies. In recent years,
some cases of liver and spleen abscesses caused by lactobacilli
have been described [106–108]. Most of these lactobacillemia
cases are associated within the population with a reduced im-
mune function. In a recent comprehensive review on probi-
otic infections in patients receiving probiotics in conjunction
with nutritional support, it appeared that all 20 case reports
of adverse events in 32 patients involved infections due to
Lb. rhamnosus GG or Saccharomyces boulardii; the risk factors
included central venous catheters and disorders associated
with increased bacterial translocation [109]. The dominance
of these two probiotic species in these reported cases may
be linked to their wider use in clinical settings rather than
their increased virulence. The question if food containing
probiotics is at the origin of the endocarditis cases is not
clear because Lactobacillus isolates from blood cultures and
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from commercial dairy products are different based on the
carbohydrate fermentation [110]. Another report described
the case of a person suffering from a Lactobacillus-associated
endocarditis after having teeth extracted due to caries. The
nongastrointestinal way of consumption is maybe at the ori-
gin of this infection [111]. In general, it could be said that the
frequency of Lactobacillus infective endocarditis is very low,
between 0.05 and 0.4% of the total of bacterial endocarditis
cases. The results should be handled with care due to false
or incomplete identification of the strains in some studies,
which highlighted the necessity of molecular tools for strain
identification [112].
In contrast to Lactobacillus spp., the genus Enterococcus
has a higher potential safety risk, although enterococci are
used as starter cultures in the food industry as well as probi-
otics [73, 113], it is emerging as a major cause of nosocomial
infection causing endocarditis, bacteremia, central nervous
system infections, neonatal infections, urinary tract infec-
tions and other infections, and its isolates are increasingly
found to carry virulence factors [114]). The origin of ente-
rococcal pathogenicity is linked to factors involved in adhe-
sion, translocation, and immune evasion [115]. A multiplex
PCR can be used for the detection of the presence of spe-
cific enterococcal virulence genes such as asa1, gelE, cylA,
esp, and hly [116]. As an example, none of the 12 probiotic
E. faecium strains tested by this multiplex PCR tested posi-
tive for the virulence genes. This multiplex PCR can be used
for testing the intrinsic virulence capacity of a strain and,
together with other molecular typing methods, it could be
an additional criterion in assessing the safety of new po-
tential probiotic E. faecium isolates [25]. Enterococcus faecalis
carries a pathogenicity island of 153 kb containing several
virulence factors and is, therefore, believed to be more viru-
lent than E. faecium, although horizontal transfer of the entire
pathogenicity island into the chromosome of E. faecium has
been demonstrated [117, 118]. Enterococcus faecium is mostly
used as probiotic like in four commercial tablet products in
Japan, although they are mislabeled as containing E. faecalis
[119].
Probiotic Bacillus strains are gaining increasing interest
because their spore-forming capacity has obvious advantages
in relation to stability and viability of the probiotic product
when this contains spores instead of vegetative cells [17].
Moreover, it has become apparent in recent years that sev-
eral Bacillus species, such as B. subtilis, have adapted to a
lifestyle in the gastrointestinal tract [120]. The use of Bacillus
spores as probiotic implies the direct consumption of high
concentrations of viable cells. One of the commercial prod-
ucts produced in Europe and marketed in at least three EU
countries (a.o. Belgium), namelyBactisubtil, seems to contain
B. cereus spores, although the product label originally men-
tioned B. subtilis. The same strain as in Bactisubtil has also
been used in the animal feed product Paciflor, which has been
withdrawn in 2002 from production due to the ability of the
strain to produce diarrhea enterotoxins hemolysin BL (from
B. cereus) (hemolytic enterotoxin complex) and nonhemolytic
enterotoxin. Two other human probiotics produced outside
Europe (Biosubtyl and Subtyl in Vietnam and Biovicerin in
Brazil) also contain B. cereus spores. Strains belonging to the
B. cereus group are known to be able to cause two kinds of
food-borne illness (Belgian Superior Health Council, 2009).
First, there is an emetic (vomiting) illness due to the inges-
tion of food containing the heat-stable toxin cereulide. The
second is a diarrheal infection due to the ingestion of B.
cereus strains producing heat-labile enterotoxins in the small
intestine. Several published PCRs for these virulence genes
or toxins could be used to screen B. cereus group strains [121].
Detection of toxin genes in B. cereus allows assessment of
the enterotoxic potential of an isolate, but not necessarily
of its enteropathogenicity. Cytotoxicity tests can be used as
an approximate estimation of the latter in the absence of
other valid tests. Nevertheless, the detection of the presence
of toxin genes by PCR-based approaches remains important
for strain characterization of B. cereus. Probiotic products can
also contain strains of, for example, B. licheniformis, B. clausii,
B. subtilis, and B. pumilus. Although much less important in
food-poisoning incidents, strains of several of these Bacillus
species are also known to be potential producers of heat-stable
or heat-labile toxins [122]. Because the B. cereus toxin PCRs
are specific for this species and not valid for detection of tox-
ins in other Bacillus species, at present only a cytotoxicity test
can be performed to exclude any pathogenic opportunity of
the Bacillus strain in question [122].
Eschericha coli Nissle strain 1917 is a well-known pro-
biotic strain used in clinical trials to treat ulcerative coli-
tis [123]. Yet, treatment with this strain has also been as-
sociated with sepsis such as a case of severe sepsis in a
preterm infant [124]. Using a mice model, the safety of E.
coli Nissle strain 1917 was assessed under different condi-
tions of defective immunity and intestinal microbiota [80].
It was found that if both the microbiota and adaptive im-
munity are defective, the strain may have potentially severe
adverse effects. For other E. coli strains that would be consid-
ered as potential probiotics, it is important to ascertain that
they do not belong to one of the pathogenic E. coli groups,
such as Shiga-toxin-producing, enterohaemorrhagic, entero-
toxigenic, enteroinvasive, enteropathogenic E. coli, etc. [125].
Several multiplex PCRs are described to investigate if an E.
coli strain contains virulence genes and belongs to one of
these pathogenic groups [126].
Propionibacteria and bifidobacteria belong both to the
coryneform bacteria and are used in (probiotic) dairy prod-
ucts. The safety of these bacteria as dairy microorganisms
has been recently reviewed [126]. In contrast to the cuta-
neous Propionibacterium spp. or the so-called “acnes group”,
the dairy Propionibacterium spp. are regarded as safe and do
not carry any known virulence factor, although P. thoenii
and P. jensenii strains show -hemolytic activity. Bifidobac-
terium is among the safest genera used as probiotics and
the risks of healthy consumers being seriously infected by
eating dairy products containing bifidobacteria are extremely
low. Nevertheless, as bifidobacteria are commonmembers of
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the human intestinal microbiota, they may behave as oppor-
tunistic pathogens like other commensal bacteria and indeed
some commensal bifidobacteria have been connected with
certain dental infections, pulmonary infections, bacteremia,
abscesses, and bloodstream infections. The nonprobiotic B.
dentium is the only bifidobacterial species classified as a
pathogen.
Saccharomyces cerevisiae var. boulardii (present in
Enterol R©) has been associated with cases of fungemia [128].
Several factors constitute excessive and undue risk for de-
velopment of Saccharomyces fungemia during probiotic ad-
ministration. These factors are the patient’s immunocompro-
mised state during critical illness, the potential for live yeast
spore contamination by the healthcare workers’ hands during
preparation of the probiotic capsule or sachet for administra-
tion, and introduction of live yeast from contaminated hands
(even after hand washing) to catheter sites [129].
Currently, probiotics or synbiotics are being used experi-
mentally in patients hospitalized in intensive care units, so-
called critically ill patients, because in these patients signif-
icant alterations in the gut microbiota occur that can lead
to severe sepsis with associated multisystem organ dysfunc-
tion and death. It remains uncertain whether the use of
probiotics or synbiotics in these circumstances is benefi-
cial or even dangerous to the clinical outcome. There is a
need for well-designed multicenter studies with a defined
mixture of bacteria on a defined group of critically ill pa-
tients before any conclusion can be drawn. In addition, the
end-points have to be clearly defined [130]. Recently, it has
been concluded from a clinical trial of probiotic prophylaxis
in predicted severe acute pancreatitis patients, that probiotic
prophylaxis should not be administered in this category of pa-
tients because the probiotic preparation used (Ecologic R© 641
consisting of six strains of viable and freeze-dried bacteria,
namely Lactobacillus acidophilus, Lb. casei, Lactobacillus sali-
varius, L. lactis, Bifidobacterium bifidum, and Bifidobacterium
lactis in a total daily dose of 1010 bacteria) did not reduce the
risk of infectious complications and was even associated with
an increased risk of mortality [131]. Following the publica-
tion of this report, several reactions of colleagues appeared
among which probiotics should only be contemplated if the
integrity of the gastrointestinal tract is not severely compro-
mised [132]. In a recent comprehensive review on probiotic
infections in patients receiving probiotics in conjunctionwith
nutritional support, it appeared that only 3 out of 53 trials,
in which 4131 patients received probiotics, showed increased
complications, which were largely noninfectious in nature
and in specific patient groups (e.g. transplant and pancreati-
tis) [109]. The authors recommend preliminary safety trials
when a probiotic is to be investigated for the first time in
a patient group receiving nutritional support and that cau-
tion should be taken in patients with risk factors for adverse
events.
With the advent of next-generation sequencing tech-
niques, the number of full bacterial genomes being se-
quenced has rapidly increased. In Table 3, >60 complete
genomes of bifidobacterial and LAB species used as pro-
biotics are listed, and >100 more genomes are being se-
quenced. Comparative genomics are now being used to find
core genes, niche-specific genes, and genes linked to specific
probiotic traits, but can as well be used to find or exclude
virulence or antibiotic resistance genes or to find indications
of chromosomal integration of horizontally acquired DNA
(e.g. sequence context screening of tRNA genes), which could
indicate the potential of horizontal transfer of virulence or
resistance genes. For example, from a comparative genomic
analysis between a probiotic and a clinical E. faecalis strain,
it seems that several of the above–mentioned enterococcal
virulence factors present are absent in the probiotic strain E.
faecalis Symbioflor I [133]. Likewise, a genomic comparison
between the probiotic strain E. coli Nissle 1917 and other E.
coli strains has indicated the lack of defined virulence fac-
tors (i.e. -hemolysin, P-fimbrial adhesions) in the probiotic
strain [134], but another study indicated that genetic varia-
tions (e.g. mutations) and gene expression differences, rather
than genomic content of virulence genes per se, contribute
to the divergence in the pathogenic traits between E. coli
strains [135].
3.5 Metabolic activities associated with production
of toxic substances
Another requisite of probiotics is that the probiotic bacteria
should not produce harmful substances by metabolic activ-
ities. One way to test this is to assess whether the strain
converts food components or biological secretions into sec-
ondary substances harmful to the host. For example, some
intestinal bacteria are known to convert proteins and their
digested products into ammonia, indol, phenols, and bio-
genic amines (histamine, tyramine, putrescine, etc.) [136].
There are no real indications on the production of harm-
ful compounds by Lactobacillus and Bifidobacterium species.
Araya-Kojima et al. [137,138] measured the enzyme activities
related to the consumption and generation of ammonia in Bi-
fidobacterium species of human origin. Compared with other
bacteria of the intestinal microbiota, Bifidobacterium species
have a lower deaminase activity involved in the production of
ammonia from amino acids but a higher ammonia assimila-
tion activity. Secondary bile acids are important harmful sub-
stances that are produced by intestinal bacterial actions on
body secretions. They may exhibit carcinogenicity by acting
on the mucous-secreting cells and promoting their prolifer-
ation, or they may act as promoters of carcinogenesis [139].
Many intestinal bacteria, includingBifidobacterium and Lacto-
bacillus species, can deconjugate conjugated bile acids [140].
However, Bifidobacterium spp., Lactobacillus spp., Leuconos-
toc lactis subsp. lactis and S. thermophilus have been reported
to lack the 7-dehydroxylase activity that is related to the
production of secondary bile acids [141, 142]. For Enterococ-
cus, cytolytic substance and other virulence factors have been
reported [143].
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3.6 Platelet-aggregating activity and mucus
degradation activity
Platelet-aggregating activity has been considered to be a re-
quired test in the assessment of probiotic safety. Aggregation
of platelets by bacteria is thought to contribute to the pro-
gression of infective endocarditis [144]. In this context, it has
been reported that platelet-aggregating activities of Lb. rham-
nosus and Lb. paracasei subsp. paracasei isolated from infec-
tive endocarditis, laboratory strains of the same species, and
strains of the species Lb. acidophilus, Lb. fermentum, Lb. oris,
Lb. plantarum, and Lb. salivarius are very strain specific [145].
The aggregation is thought to be associated with the pro-
teins on the outer cell layer. The properties of the outer cell
layer have been measured by hydrophobicity, hydroxyapatite
adhesion, and salivary aggregation. Lactobacillus rhamnosus
strains isolated from infective endocarditis have higher activ-
ities than do laboratory strains of Lb. rhamnosus [146]. As for
the other virulence factors, the activities of glycosidases and
proteases (arylamidase), which might enable the breakdown
of human glycoproteins and the synthesis and lysis of hu-
man fibrin clots, have been measured in Lb. rhamnosus, Lb.
paracasei subsp. paracasei, and other strains. Some strains
produce these enzymes, suggesting that they may have an
infective property in causing endocarditis [147]. However, a
study that aimed to measure the enzymatic activities relating
to degradation of intestinal mucus glycoprotein in several
strains of Lactobacillus and Bifidobacterium found no such
activity in these strains [148]. Further research on the struc-
ture of the outer cell layer or the above-mentioned enzyme
activities in probiotic bacterial strains is expected. Whether
the outer layer structure, which contains surface proteins,
glycoproteins, and lectins, is really related to infectivity and
whether glycosidases, proteases (arylamidase), and other en-
zymes capable of degrading human intestinal cells are related
to infection remain to be elucidated.
3.7 Safety parameters “under debate”: colonization,
adhesion, and translocation
As mentioned above, the QPS list used in Europe describes
the microorganisms that can be considered safe for use in
food applications. Members on this list often have “a long
history of safe use”, without any negative effect mentioned
in the literature. The QPS list is based on identification at
the species level, while it is generally accepted that probiotic
effects are strain specific. It is fair to say that also virulence fac-
tors are strain specific and may vary largely within a species.
As an example, E. coli is often mentioned. This species com-
prises harmless commensal strains, which we all carry with
us without any problem, but pathogenic strains which are,
for instance, enteroinvasive E. coli (www.fda.gov/Food/Food
Safety/FoodborneIllness/FoodborneIllnessFoodbornePatho
gensNaturalToxins/BadBugBook/ucm071298.htm) or en-
terohemorrhagic E. coli (www.fda.gov/food/foodsafety/
foodborneillness/foodborneillnessfoodbornepathogensnatur
altoxins/badbugbook/ucm071284.htm) are widely known
and studied. Underlying mechanisms for invasiveness and
pathogenicity are gradually being understood, although
many uncertainties remain.
In the process of infection and invasion, three aspects
may be important: a first contact or adhesion between the
bacterial strains and the epithelial cells, a further transloca-
tion of the strain into or through the intestinal epithelium
and proliferation in the sterile body site, either at the level
of the lamina propria, the mesenteric lymph nodes, or sys-
temically [149, 150], leading to sepsis, endocarditis, and bac-
teremia [151]. For this reason, it has been suggested that the
adhesion and translocation potential of a strain should be
considered as part of the safety evaluation of probiotics [152].
Adhesion has been considered as a possible probiotic
characteristic, since adhesion can prolong the intestinal
colonization of the probiotic strain, improve the beneficial
immune interactions, occupy receptors that could otherwise
also “accommodate” pathogens and fortify the intestinal bar-
rier. Clearly, the subject is controversial and further research
into the many factors that may influence the outcome of ad-
hesion tests is required. Different tests, different epithelial
cell lines, whether or not mucus was included, or simply dif-
ferent laboratories all seem to result in different findings. In
addition, also the physiological status of the bacteria seems
to matter and, consequently, many doubts exist on the value
of in vitro tests to predict the in vivo effect of a particular
strain. Adhesion may also depend on the local competition
with the commensal microbiota, on the number of bacteria
consumed, and above all, eventual translocation will heavily
depend on the immune status of the hosts. Effects of translo-
cated bacteria may also be very different. The way to deal with
this is far from clear given that the absence of pathogenicity
and infectivity is a prerequisite of probiotic safety. The isola-
tion of LAB or bifidobacteria from clinical cases, however, is
likely to be the result of opportunistic infections [153–155].
To some extent, the increasing isolation rate from these in-
fections may be due to an increased awareness of the role
of these bacteria in opportunistic infections, or may result
from the use of improved identification methods. A sensible
approach in studying this would be to consider the question
whether invasion of the host by the bacteria leads to infection
and whether infection results in a severe outcome [156].
Translocation is probably a much more important phe-
nomenon than adhesion, as adhesion without transloca-
tion is rarely a problem and could, as argued above, even
be beneficial. Systemic infection by intestinal bacteria after
translocation is a cause of opportunistic infection in immuno-
compromised hosts [157,158] and may be linked to intestinal
mucosal injury, immunodeficiency of the host, or bacterial
overgrowth [156, 159, 160]. “Infective” bacterial translocation
from the intestine is difficult to induce in healthy animals
[161, 162], although “controlled” bacterial translocation can
be seen as a highly regulated, physiological event that occurs
continuously in healthy subjects at a low rate [162]. When the
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integrity of the intestinal barrier is disturbed or when the im-
mune system is not able to confine an infection, pathogenic
or commensal bacteria can reach the bloodstream and cause
septicemia [163]. Therefore, antibiotic treatment, administra-
tion of immunosuppressive agents, or induction of colitis are
used to measure bacterial translocation [152,162,164]. While
bacterial translocation does not occur easily in healthy spe-
cific pathogen-free animals, it is known to occur for a long
duration in germ-free mice [156, 165, 166], linked to the im-
mature intestinal barrier and the underdeveloped immune
system of these germ-free animals [167, 168].
In conclusion, assessment of the safety of probiotics from
various angles is not a simple task [156]. The test item that
has been attracting attention is whether the bacteria possess
infectivity. Assessment of the ability to cause opportunistic
infection is difficult. The acute and chronic toxicity tests prob-
ably provide circumstantial evidence. However, observations
of the passage of bacteria across the intestinal barrier and in-
vasion of the host body by translocation provide more direct
data for determining infectivity.
3.8 Genetically modified microorganisms (GMMs)
Alongside natural bacterial and yeast strains, GMMs have
been designed to treat specific diseases by targeting specific
pathogens and/or toxins, or through the delivery of immuno-
suppressive proteins (reviewed in [169]). The use of these
so-called designer probiotics in humans effectively means
that GMM are deliberately released into the environment,
which calls for specific measures and monitoring to guar-
antee their safety. Such measures include well-documented
evidence that probiotic GMM (i) do not possess antibiotic se-
lection markers, (ii) cannot accumulate in the environment,
and (iii) cannot transfer their genetic modification(s) to other
(micro)organisms [170]. The most challenging of these is
the prevention of environmental accumulation that can be
achieved through active and/or passive biological contain-
ment. Active containment is achieved by the production of a
compound toxic to the GMM under regulation and control
of an environmentally responsive element, whereas passive
containment relies on complementation of an auxotrophy by
supplementation with either an intact gene or the essential
metabolite (for review see [171]). The latter method was ap-
plied in the design of a recombinant interleukin-10-producing
L. lactis strain for treatment of Crohn’s disease patients [172].
This recombinant is deficient for the thymidylate synthase
gene (thyA), which is essential for growth of Lc. lactis, and
thus holds a negligible risk to accumulate and spread in the
environment in the absence of thymine or thymidine.
4 Quality control of final products
4.1 Microbial contamination of the final product
Probiotic foods have steadily gained popularity over the past
decades and a wide variety of foods nowadays contain pro-
biotic cultures. Strains are selected based on their specific
health-promoting effects, but it is obvious that the safety as-
pects are also carefully considered to ensure that they do not
pose any health risk for the consumer. The safety evaluation
usually includes screening for (transferable) antibiotic resis-
tance genes, virulence or pathogenic properties, undesirable
metabolic activities, and collection of evidence to demonstrate
a “history of safe use”, etc. [82]. Once a strain has been ap-
proved, it must still be determined whether the analytical
methods that are normally used to verify the microbiologi-
cal safety of the ingredients and the finished products can
also be used for the product with the probiotic strains. For
microbiological methods, this is not very obvious.
Finished products typically contain ca. 7 to 8 log colony-
forming unit (CFU) per gram and the initial starter may con-
tain more than 11 log CFU per gram, so it should be taken
into account that the presence of undesirable contaminants
is masked by the abundance of the beneficial microorgan-
isms. Theoretically, this problem is most likely to occur with
nonselective cultural methods. However, even with selective
methods, this possibility should be considered, in particu-
lar because many of these methods include a nonselective
preenrichment step. This is, for instance, the case for various
internationally recognized protocols, for example, for the iso-
lation and detection of Salmonella (ISO standard 6579:2002).
Joosten et al. [173] clearly demonstrated that false-negative
results could be obtained for the detection of Salmonella in
infant powder with probiotics. The high incidence of false-
negative results can probably be explained by the metabolic
activities, properties of the probiotic bacteria, in particular
the production of organic acids, whose accumulation could
render the preenrichment broth into a hostile environment
for Salmonella. By using double-strength buffered peptone
water supplemented with vancomycin (10 g/mL) and mala-
chite green (100 g/mL) and nonfat dry milk powder (10
g/L) as preenrichment medium, the recovery of Salmonella
was much better [173]. For the detection of other pathogenic
bacteria, especially when a nonselective enrichment is used,
a similar problem could be observed. By adding antimicro-
bial compounds to selectively suppress the growth and/or
metabolic activity of the probiotic bacteria, this problem
could be resolved, but still more research is needed to op-
timize such enrichment procedures. For the enumeration of
the total microbiota, especially the contaminating microbiota
(without the enumeration of the probiotic strain), the addi-
tion of 2% sodium phosphate or 5% glycerophosphate could
solve the problem [174]. To study more in detail the problem
of detection of contaminants in starter cultures and probi-
otics, a specific ISO working group started in 2010 (ISO/TC
34/SC9).
4.2 Microbial composition
Several research labs have independently analyzed the mi-
crobial composition of probiotic dairy products [14, 23, 24,
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175–177]. The overall conclusion from these studies is that
a considerable number of dried food supplements and-–
although to a much lesser extent–-dairy products are incor-
rectly or inadequately labeled, with regard to the correct iden-
tity of the incorporated probiotic strains. At a time when
consumers become more and more aware of the important
link between nutrition and health, it is thus of paramount
importance that probiotic products with claimed health-
promoting effects are well controlled regarding their mi-
crobial composition. Ideally, microbial analysis of probiotic
products relies on standardized and accurate procedures for
both the isolation and the identification of the implemented
strains. In practice, however, microbial quality control of
probiotic products is carried out using a culture-dependent
or a culture-independent approach, or a combination of
both, with each of these approaches having specific draw-
backs and limitations. Especially in the case of multispecies
products, a reliable taxonomic inventory may be difficult to
achieve.
In a culture-dependent approach, the most crucial step is
the recovery of the probiotic strain(s) from the product ma-
trix, using one or more selective isolation media [178, 179].
Some probiotic strains are the result of isolation campaigns
that employed very specific growth conditions that are not
always provided by commercial media or by the standard
set of incubation parameters used for isolation. In this con-
text, it has been shown that especially Bifidobacterium strains
may be hard to recover from the original products, and that
selective isolation of bifidobacteria from products that also
contain LAB is not always straightforward [23,177]. Although
still far from optimal, improved protocols and selective me-
dia with a higher performance have been proposed for spe-
cific enumeration and isolation of bifidobacteria from (pro-
biotic) samples [23,180]. After isolation, a limited number of
colonies are usually subjected to taxonomic characterization
for the purpose of species identification as described above.
When the most optimal isolation conditions are applied but
culture-dependent analyses are negative, it can be concluded
that the targeted bacteria are either absent or are present in
numbers beneath 1000 CFU/mL or CFU/g, which is gener-
ally considered to be the detection limit of culture-dependent
analyses.
In order to circumvent the possible pitfalls of conventional
culturing, culture-independent methods are increasingly be-
ing used for both qualitative and quantitativemicrobial analy-
sis of probiotic products, because itmay overcome someof the
major disadvantages or limitations of culture-dependent ap-
proaches in terms of speed, taxonomic resolution, and repro-
ducibility, Denaturing gradient gel electrophoresis (DGGE)
is a DNA fingerprinting technique that has been widely used
to unravel the microbiological composition of commercial
probiotic products [23, 24, 181–183]. Essentially, the DGGE
method relies on (i) the isolation of total genomic DNA from
the probiotic product, (ii) the selective amplification of a
hypervariable region of the 16S rRNA gene by community
PCR, and (iii) the electrophoretic separation of the result-
ing pool of PCR amplicons based on sequence content using
DGGE [184]. In theory, the resulting DGGE fingerprint will
visualize all species present in a given probiotic product by a
unique band, which can be identified by band position analy-
sis, band sequencing, and/or band hybridization. Despite the
simplicity of its methodological concept, however, the inter-
pretation of a DGGE fingerprint requires specific expertise,
as some band positionsmay coincide with those of other phy-
logenetically closely related bacteria, some species may be
represented by multiple bands due to the so-called 16S rDNA
multi-operon effect, or species present in numbers beyond
the detection level may not be visible [184]. To improve the
detection capacity of DGGE, group-specific primers can be
used [184].
Although DGGE has been successfully used to deter-
mine the microbiological composition of probiotic products,
it does not provide a lot of information regarding the relative
number of each species present. As discussed elsewhere in
this report, a range of validated 16S rRNA-targeted oligonu-
cleotide probes is available for the identification of LAB rang-
ing fromgroup and genus to species and subspecies level [28].
Commonly, these probe sequences are converted to genus-
, species- or strain-specific PCR primers in the design of
real-time quantitative PCR assays to assess the relative con-
centration of the constituting strains and species in a given
probiotic product [185–187].
4.3 Microbial concentration and stability
The quality of a microbiological product, such as a starter
or more generally a powder enriched with microbial cells,
is generally quantified by its content in microbial cells, and
among these cells two properties being expected: the ability to
divide and to display a metabolic activity when introduced in
a medium or a food composition. These properties are gen-
erally represented by a term called viability. However, recent
studies have shown that cell division and metabolic activ-
ity are not always correlated, since microbial cells are able
to reach a transient state where no cell division occurs but
metabolic activity is maintained [188], leading to a distinc-
tion between viability (or ability to divide) and vitality (related
to the metabolic activity). These observations have led to the
distinction between three classes: viable and cultivable (VC),
nonviable (NV), and viable but non cultivable (VBNC). This
last class has been the subject of intensive studies followed by
the development of a dedicated method in order to make the
distinction between VC, NV, and VBNC states [189]. The cor-
rect assignment of a probiotic product to one of these classes
is crucial, given the fact that the FAO/WHO definition of
probiotics [7] explicitly excludes NV formulations [190]. Ac-
cording to this definition, dead cells of (beneficial) bacteria
that are shown to trigger or modify biological responses such
as anti-inflammatory effects [191] should thus not be named
probiotics. However, even for quality-checked probiotic prod-
ucts in which the active strains are considered to be in a VC
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state, it has been shown that a part of the bacterial popula-
tion may become VBNC during storage [192, 193]. While the
technological and economical importance of this finding is
clear, possible effects of VC-to-VBNC transitions on probiotic
efficacy remain to be determined.
Traditional microbiological methods rely on direct count-
ing of microbial cells either by microscopy or by plate count-
ing. The second method is generally preferred, since it gives
directly the amount of cells able to divide with a result being
expressed as “colony-forming units”. However, this method
presents several drawbacks: it is labor intensive, it is sub-
jected to variability, and it is not able to display the VBNC
state. The emergence of fluorescence-based techniques has
led to a great improvement of the understanding of micro-
bial viability and its evolution throughout processes [194].
The use of specific fluorescent dyes allows to get a strong
insight into the level of the intracellular structures in rela-
tion with cell viability. The most used techniques involve
stains displaying different behaviors related to membrane
permeability and/or degree of damage. The combination of
fluorescent-based techniques with high-throughput experi-
mental techniques has led to new opportunities in order to
improve the analytical tools dedicated to the determination
of the cellular properties [195]. In this area, flow cytometry is
an emerging technology in the field of food, environmental,
and industrial biotechnology for the assessment of microbial
viability [196]. The main advantage of this method is that it
does not require a cultivation step of the microorganisms be-
fore analysis. Indeed, microorganisms present in the sample
are separated and aligned cell by cell in an optical analy-
sis chamber by a flow-focusing method. In this way, optical
properties can be acquired at the single-cell level allowing to
take into account the intrinsic heterogeneity of the microbial
population (heterogeneity has been observed even in a clonal
population). In addition to the above-mentioned advantages,
a flow cytometry-based method can be automated in order to
follow cell properties on-line during a process. It can also be
applied to follow product quality during storage after down-
stream processing steps, such as freeze drying and spray
drying [197].
4.4 Strain authenticity and genetic stability
The authenticity of a probiotic culture is an important crite-
rion to ensure the expected quality and thus predicted health-
promoting effect of the probiotic product. Linked to strain
authenticity is genetic stability, which reflects the susceptibil-
ity of the culture concerning genomic rearrangements in the
course of its natural evolution. These rearrangements may
reflect small variations introduced at specific or random posi-
tions of the genome through point mutations, deletions, and
insertions, but may also be linked to larger structural vari-
ations resulting from homologous recombination (vertical
inheritance) and horizontal gene transfer events. Although
this is a highly relevant issue in order to ensure that specific
health-promoting characteristics and functionalities are not
affected during long-term preservation and production, few
studies have reported comprehensive data documenting the
genetic stability of commonly used probiotic strains. Ideally, a
rigorous assessment of a strain’s genetic stability requires the
availability of its whole-genome sequence. In the absence of
this information, however, the use of molecular typing tech-
niques probably provides the best estimate of genetic stability
at the individual strain level.
A preliminary verification of bacterial strain authenticity
can be obtained by partial 16S rRNA gene sequencing. If this
analysis confirms the species identity of the probiotic culture,
further characterization at strain level may be required. Else-
where in this report, a series of typing methods is discussed
which could be used for this purpose. However, as different
typing methods offer different levels of genotypic resolution,
the choice of themethod and the appropriate protocol are cru-
cial. As far as DNA fingerprinting approaches are concerned,
AFLP analysis and PFGE of macrorestriction fragments of-
fer the highest resolution at strain level. These two methods
are excellent tools for genotypic comparisons throughout the
production or shelf-life period of a product. Sequence-based
approaches such as the MLST schemes developed for sev-
eral Lactobacillus and Bifidobacterium species are also relevant
for typing of probiotic cultures, although their usefulness in
strain authenticity matters still needs to be verified. Although
not supported by producers and distributors of commercial
probiotic products, deposit of probiotic cultures into an in-
ternationally recognized culture collection would provide an
enduring source of reference material for confirmation of
genetic stability.
Although it is generally assumed that Lactobacillus and
Bifidobacterium strains used in probiotic applications show
a high genotypic stability under different production condi-
tions, more direct and in-depth evidence for this hypothesis
is needed. Ideally, this should be done using a series of dif-
ferent molecular typing methods or, ultimately, comparative
genomics. A number of genome projects have revealed that
species used in probiotic products have specifically adapted
themselves to specific environments. This is exemplified in
the genomes of Bifidobacterium longum subsp. longum and
Bf. longum subsp. infantis by the presence of many genes
involved in the uptake and utilization of host-indigestible
complex carbohydrates and polyols, supporting their genome
adaptation to the human large intestine, where these are the
predominant nutrient sources [198, 199]. The genome of L.
delbrueckii subsp. bulgaricus, which is applied worldwide in
yogurt production, is in a phase of rapid reductive evolution,
as a possible result of its adaptation from a plant-associated
habitat to amilk environment through the loss of superfluous
functions and protocooperation with S. thermophilus [200]. In
the same way, comparative genomics could also determine
the potential of probiotic strains to acquire and/or transfer
DNA elements during host passage and long-term coloniza-
tion, which is a research area that has remained virtually
unexplored.
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4.5 Labeling and claims
Official controls by national authorities are performed to en-
sure verification of compliance with food law. Apart from
the risk of using unauthorized strains, product mislabel-
ing is a known problem, partly because of the use of phe-
notyping or genotyping methods with a lack of discrimi-
native power [21]. In addition to official controls, private
controls by food-producing companies are important in the
frameof protection of patented strains and industrial property
rights.
In their “Guidelines for the Evaluation of Probiotics in
Food” document, the FAO/WHO working group [10] recom-
mends that the following information should be described on
the label of probiotic products:
(i) genus, species, and strain designation. Strain designa-
tion (definition) should not mislead consumers about
the functionality of the strain;
(ii) minimum viable numbers of each probiotic strain at the
end of the shelf-life;
(iii) the suggested serving sizemust deliver the effective dose
of probiotics related to the health claim;
(iv) health claim(s);
(v) proper storage conditions;
(vi) corporate contact details for consumer information.
Inmost countries, only general health claims are currently
allowed on foods containing probiotics. The FAO/WHO
working group [10] recommended that specific health claims
on foods be allowed relating to the use of probiotics, where
sufficient scientific evidence is available. Such specific health
claims should be permitted on the label and promotional ma-
terial. For example, a specific claim that states that a probiotic
“reduces the incidence and severity of rotavirus diarrhea in
infants” would be more informative to the consumer than
a general claim that states “improves gut health”. It is rec-
ommended that it has to be the responsibility of the prod-
uct manufacturer that an independent third party review by
scientific experts in the field be conducted to establish that
health claims are truthful and not misleading. In line with
the suggestions of the FAO/WHO working group [10], in
2006 the European Parliament and the Council published a
novel regulation (Regulation (EC) No. 1924/2006) on “Nu-
trition and Health Claims Made on Foods”) [12]. This reg-
ulation applies to all nutritional and health claims relating
to all types of food intended for final consumers, thus also
including probiotic products brought to the market with a
health claim. The regulation aims to harmonize the nutrition
and health claims at European level in order to better protect
consumers, including commercial communications (label-
ing, presentation, and promotional campaigns) and trade-
marks and other brand names that may be construed as
nutrition or health claims. The regulation establishes the
authorization procedures required to ensure that claims on
food labeling, presentation, and advertising are clear, con-
cise, and based on evidence accepted by the whole scientific
community.
5 Concluding remarks
The first objective of Working Group “8651 Probiotics” of
the Belgian Superior Health Council was to review the state
of knowledge as regards to the methodologies for the mi-
crobiological characterization of strains and products with
purported probiotic activity. Above all, this advisory report
illustrates that characterization of probiotics in terms of tax-
onomic identity, biological safety, and product quality is a
challenging task that requires a multidisciplinary approach.
In addition, it also helps to reinforce current or even identify
new research opportunities. For instance, the ongoing inte-
gration and translation of massive (meta)genomic datasets
into knowledge and tools that allow more accurate determi-
nation of a strain’s identity, a better demonstration of its
safety and more powerful prediction of its functionalities
are still in their infancy, but will have important implica-
tions in the development of new probiotic formulations as
well as a better mechanistic understanding of the existing
ones [201, 202]. For characterization and quality control of
multistrain and multispecies formulations especially, high-
throughput pyrosequencing approaches are expected to be-
come a standard soon.Also, little is knownabout the impact of
food format and food ingredients on the survival, physiology,
and efficacy of the incorporated probiotic strain(s) [203, 204].
Such information is essential to determine and predict possi-
ble differences in the behavior of a strain in pure culture or in
a food product, but also to challenge the degree of flexibility
of regulatory standards and recommendations in the context
of bioequivalence.
The few examples mentioned above clearly indicate that
probiotics are one of the key areas in food research where
academics, industry, regulatory agencies, health profession-
als, and policy makers are destined to communicate and col-
laborate in the interest of consumer and patient. This advi-
sory report hopes to provide a benchmark for ongoing and
future developments in the microbial characterization of pro-
biotics, and will in due course be followed by a second report
of Belgian Superior Health Council Working Group 8651
focusing on functional properties and health prospects of
probiotics.
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